Binds Virus Or Component Or Product Thereof (e.g., Virus-associated Antigen, Etc.) Patents (Class 530/389.4)
-
Publication number: 20090081124Abstract: The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occn-panty of co-receptor present on the cell, for example. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CCR5 and CXCR4 sequences.Type: ApplicationFiled: November 15, 2007Publication date: March 26, 2009Inventors: Anthony Louis DeVico, Timothy R. Fouts, Robert G. Tuskan
-
Publication number: 20090081202Abstract: Disclosed are immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating microbial infection, including, for example, influenza, or one or more symptoms thereof.Type: ApplicationFiled: August 27, 2008Publication date: March 26, 2009Applicant: Longhorn Vaccines & Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Publication number: 20090030187Abstract: The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least one thioether cross-link that specifically bind to particular antigens. The present invention also provides a composition comprising a macromolecule substantially free of a denaturing reagent, wherein the macromolecule comprises at least one thioether cross-link. In addition, the present invention provides a method for producing the macromolecules and compositions of the invention.Type: ApplicationFiled: March 14, 2006Publication date: January 29, 2009Inventors: Guillermo I. Tous, Mark Schenerman, Ziping Wei
-
Publication number: 20080193418Abstract: The invention provides bacteriophages that infect Bacillus bacteria, including Bacillus anthracis, and compositions containing the bacteriophages. The invention also provides methods for using the bacteriophages of the invention to detect, prevent and treat infection of an organism by Bacillus bacteria. Methods and materials to decontaminate a surface or an organism that is contaminated with Bacillus bacteria or Bacillus spores are also provided.Type: ApplicationFiled: June 6, 2005Publication date: August 14, 2008Inventor: Michael H. Walter
-
Publication number: 20080187545Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.Type: ApplicationFiled: June 6, 2007Publication date: August 7, 2008Inventors: Thomas Shenk, Dai Wang
-
Patent number: 7364737Abstract: Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell line producing the monoclonal antibodies.Type: GrantFiled: January 29, 2004Date of Patent: April 29, 2008Assignee: The Scripps Research InstituteInventors: Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
-
Publication number: 20080044426Abstract: The invention relates to the field of virology. The invention provides a new isolated essentially mammalian positive-sense single stranded RNA virus (EMCR-CoV) within the group of coronaviuses and components thereof.Type: ApplicationFiled: November 18, 2004Publication date: February 21, 2008Inventors: Jan Cornelis De Jong, Theodorus Marinus Bestebroer, James Henry Matthew Simon, Ronaldus Adrianus Maria Fouchier, Albertus Dominicus Marcellinus Osterhaus
-
Patent number: 7314919Abstract: An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof.Type: GrantFiled: June 11, 2002Date of Patent: January 1, 2008Assignee: Biostrands S.r.l.Inventors: Roberto Burioni, Massimo Clementi
-
Patent number: 7244427Abstract: A new protein derived from acid hydrolyzed IgG concentrate which has a molecular weight of about 55,000, and is activated by heat within the defined narrow temperature range provides resulting product that has a protective mechanism for bacterial and viral invasion of living cells.Type: GrantFiled: January 30, 2001Date of Patent: July 17, 2007Assignee: The Lauridsen Group IncorporatedInventors: Ralph D. Yoder, Ronald E. Strohbehn
-
Patent number: 7112664Abstract: The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombinant vector.Type: GrantFiled: December 4, 2003Date of Patent: September 26, 2006Assignee: Yuhan CorporationInventors: Jong Wook Lee, In Young Ko, Heui Keun Kang, Jung Hyun Nam, Moo Young Song, Hyung Jin Moon, Tae Hun Song
-
Patent number: 7101554Abstract: A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects of the invention comprise a protein corresponding to a protein of the picornaviruses, antiserum or antibody directed against a protein of the picornaviruses, antigen comprising a protein of the picornaviruses, diagnostic kits, vaccines, use of the picornaviruses in medicaments, particularly for the treatment or prevention of Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatique Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, and Sudden Infant Death Syndrome, and methods of treatment of diseases caused by the picornaviruses.Type: GrantFiled: September 9, 1997Date of Patent: September 5, 2006Assignee: Microtus ABInventor: Bo Niklasson
-
Patent number: 7091324Abstract: Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.Type: GrantFiled: December 1, 2000Date of Patent: August 15, 2006Assignee: Board of Trustees of Leland Stanford Junior UniversityInventors: Steven K. H. Foung, Kenneth G. Hadlock, Zhen-yong Keck
-
Patent number: 7087377Abstract: The invention relates to an anti HIV 1 vaccine comprising the entire or part of the Tat HIV 1 protein, in addition to the identification of said protein in individuals affected by HIV. The Tat protein is a protein of the HIV 1 Oyi variant.Type: GrantFiled: October 21, 2004Date of Patent: August 8, 2006Assignee: Centre National de la Recherche ScientifiqueInventor: Erwann Loret
-
Patent number: 7067638Abstract: This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related which makes it possible to detect most SRSV-related viruses and further to distinguish their serotypes and genogroups.Type: GrantFiled: June 22, 2000Date of Patent: June 27, 2006Assignees: Japan as represented by Director-General National Institute of Infectious Diseases, Denka Seiken Co., Ltd.Inventors: Naokazu Takeda, Katsuro Natori, Tatsuo Miyamura, Kunio Kamata, Toshinori Sato, Seiya Sato
-
Patent number: 7033593Abstract: The invention relates to an immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on the protein, and bound to an HR-2 peptide. The invention also relates to a method of inducing anti-HIV antibodies using such an immunogen.Type: GrantFiled: September 17, 2003Date of Patent: April 25, 2006Assignee: Duke UniversityInventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Patent number: 7008622Abstract: A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-terminal Pro). Vaccinal and pharmaceutical compositions can contain the antibodies induced by the peptide compositions for use in passive therapy. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.Type: GrantFiled: February 28, 2002Date of Patent: March 7, 2006Assignee: Thymon, L.L.C.Inventor: Gideon Goldstein
-
Patent number: 6984721Abstract: Immunological reagents obtained from multimeric forms of the HIV-2 and SIV envelope glycoproteins and their use in the detection of HIV-2, particularly, the HIV-2 proteins gp300, p200, p90, and p80, and gp300 of SIV.Type: GrantFiled: December 19, 2000Date of Patent: January 10, 2006Assignee: Institut PasteurInventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey-Cuillé
-
Patent number: 6982156Abstract: Antibodies directed to SPICE and VCP which may be used for detection, prevention, and treatment of variola virus or vaccinia virus are provided. Recombinant SPICE and VCP proteins are also provided which are used for enhancing the immune response to variola or vaccinia virus and modulating of complement activation. Methods and kits for detecting nucleic acid sequences encoding SPICE and VCP are also provided.Type: GrantFiled: May 20, 2003Date of Patent: January 3, 2006Assignee: Trustees of the University of PennsylvaniaInventor: Ariella M. Rosengard
-
Patent number: 6939954Abstract: A new protein derived from acid hydrolyzed IgG concentrate which has a molecular weight of about 55,000, and is activated by heat within the defined narrow temperature range provides resulting product that has a protective mechanism for bacterial and viral invasion of living cells.Type: GrantFiled: August 27, 2001Date of Patent: September 6, 2005Assignee: The Lauridsen Group IncorporatedInventors: Ralph D. Yoder, Ronald E. Strohbehn
-
Patent number: 6927281Abstract: The present invention relates to a method of detecting a causative agent of the so-called spontaneous early abortion by investigating patients' samples for the presence of adeno-associated virias DNA (AAV DNA), or AAV antigen or antibodies, preferably of the IgM type, directed to AAV. Furthermore, the present invention relates to antibodies suitable for said method.Type: GrantFiled: October 28, 1994Date of Patent: August 9, 2005Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Andrea Kern, JĂ¼rgen Kleinschmidt, Karsten Geletneky, MichĂ©le Rabreau, Jörg Schlehofer, Edda Tobiasch
-
Patent number: 6824778Abstract: In this application are described monoclonal antibodies which recognize E3 glycoprotein of alphavirus and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of alphavirus infections in vitro and in vivo.Type: GrantFiled: April 22, 2002Date of Patent: November 30, 2004Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Mary Kate Hart
-
Patent number: 6818748Abstract: A single chain variable fragment (ScFv) antibody from a monoclonal antibody (Mab) against Venezuelan equine encephalitis (VEE) virus, is generated by cloning linked variable regions of the heavy (VH) and the light (VL) chain antibody genes. Mab clone 1A4A1 in E. coli strain TG-1 was successfully cloned as ScFv. Results were reproduced in E. coli strain HB2151, expressing the same clone, A116, though displaying weak binding specificity to VEE due to a frame shift in the N-terminal region of the VL domain, upstream to the complementarity-determining region 1. A PCR-based site-directed mutagenesis approach was adopted to re-introduce the three single-base deletions in the 5 prime region of the VL gene of A116, corresponding to framework-1 region, producing mutant MA116, correcting a localized frame-shift in framework-1 region to consensus framework-1 amino acid sequence. A MA116 clone, MA116-15, shows comparable reactivity to the parental Mab in recognizing VEE antigen.Type: GrantFiled: March 13, 2002Date of Patent: November 16, 2004Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of National DefenceInventors: R. Elaine Fulton, Leslie Nagata, Azhar Alvi
-
Publication number: 20040132010Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: ApplicationFiled: September 17, 2003Publication date: July 8, 2004Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Patent number: 6685942Abstract: A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), or a monoclonal antibody comprising the fragment.Type: GrantFiled: August 26, 1997Date of Patent: February 3, 2004Assignee: The Scripps Research InstituteInventors: Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
-
Patent number: 6682909Abstract: The present invention provides truncated HCV E2 polypepides. The invention HCV E2 polypeptides lack the HVR1 region that provides immune protection against HCV. The present invention also provides immunogenic compositions of such polypeptides and the methods of use thereof.Type: GrantFiled: September 13, 2001Date of Patent: January 27, 2004Assignee: Hawaii Biotech, Inc.Inventors: Eileen T. Nakano, David E. Clements, Tom Humphreys
-
Patent number: 6680053Abstract: The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombinant vector.Type: GrantFiled: May 29, 2001Date of Patent: January 20, 2004Assignee: Yuhan CorporationInventors: Jong Wook Lee, In Young Ko, Heui Keun Kang, Jung Hyun Nam, Moo Young Song, Hyung Jin Moon, Tae Hun Song
-
Patent number: 6677127Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: September 13, 1999Date of Patent: January 13, 2004Assignee: Aventis Pasteur LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6670466Abstract: The present invention is related to mammary tumor virus (MTV). MTV represents a group of retroviruses which possess very high homology to mouse mammary tumor virus (MMTV), a virus known to cause neoplastic mammary disease in mice. As described herein, MTV's have been identified in human, cat, and Rhesus macaque. The present invention specifically provides for recombinant nucleic acids and polypeptides derived from these MTV's as well as methods for using these biological molecules.Type: GrantFiled: December 19, 2001Date of Patent: December 30, 2003Assignee: The Administrators of the Tulane Educational FundInventor: Robert F. Garry
-
Patent number: 6610295Abstract: HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary. The gH protein is encoded by DNA in the HindIII L fragment lying between 228 and 2456 bases from the L/D boundary. The genes have been incorporated in recombinant vaccinia vectors and expressed in host animals to raise HCMV-neutralizing antibody, thereby indicating vaccine potential. The glycoproteins can also be used in a variety of different ways, as vaccines or in the production, purification or detection of HCMV antibody.Type: GrantFiled: May 26, 1995Date of Patent: August 26, 2003Assignee: Cogent LimitedInventors: Geoffrey Lilley Smith, Martin Patrick Cranage, Barclay George Barrell
-
Patent number: 6610303Abstract: This invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein and a papilloma virus genome, respectively. In addition, this invention concerns proteins coded by the papilloma virus genome and antibodies directed against them as well as their use for diagnosis, treatment and vaccination.Type: GrantFiled: December 23, 1999Date of Patent: August 26, 2003Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Ethel-Michele de-Villiers-zur Hausen, Harald zur Hausen, Donna Lavergne, Claire Benton
-
Patent number: 6608179Abstract: Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.Type: GrantFiled: September 22, 1999Date of Patent: August 19, 2003Assignee: Institut PasteurInventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
-
Patent number: 6600023Abstract: Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.Type: GrantFiled: February 18, 1993Date of Patent: July 29, 2003Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 6596497Abstract: A method for the screening of antiviral compounds targeted to the HIV gp41 core structure comprising capturing polyclonal antibodies from an animal other than a mouse directed against a trimer of a heterodimer containing an N-peptide and a C-peptide onto a solid-phase, mixing a compound to be tested with an N-peptide and then adding a C-peptide, adding the resultant mixture to the resultant polyclonal antibody coated solid-phase and then removing unbound peptides and unbound compound, adding a monoclonal antibody directed against the trimer of a heterodimer containing an N-peptide and a C-peptide and measuring the antibody binding of the monoclonal antibody.Type: GrantFiled: March 14, 2000Date of Patent: July 22, 2003Assignee: New York Blood Center, Inc.Inventors: Shibo Jiang, Asim K. Debnath
-
Publication number: 20030129746Abstract: Antibodies to two new epitopes on the HCV envelope proteins were identified which allow routine detection of native HCV envelope antigens, in tissue or cells derived from the host. The new epitopes are: the E1 region aa 307-326 and the N-terminal hyper variable region of E2 aa 395-415. Surprisingly, we characterised an antibody that reacts with various sequences of the hypervariable domain of E2. Specific monoclonal antibodies directed against these epitopes and allowing routine detection of viral antigen are described.Type: ApplicationFiled: December 13, 2002Publication date: July 10, 2003Applicant: INNOGENETICS N.V.Inventors: Geert Maertens, Erik Depla, Marie-Ange Buyse
-
Patent number: 6558898Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.Type: GrantFiled: June 7, 1995Date of Patent: May 6, 2003Assignee: Abbott LaboratoriesInventors: John N. Simons, Tami J. Pilot-Matias, George J. Dawson, George G. Schlauder, Suresh M. Desai, Thomas P. Leary, Anthony Scott Muerhoff, James Carl Erker, Sheri L. Buijk, Isa K. Mushahwar
-
Patent number: 6557296Abstract: This invention is directed toward mutated DNA, proteins, or protein fragments and particles from the L-2 cell line. The invention is also directed to diagnostic, prophylactic and therapeutic methods of making and using the DNA, proteins and particles.Type: GrantFiled: July 30, 2001Date of Patent: May 6, 2003Assignee: The Immune Response CorporationInventor: Ronald B. Luftig
-
Publication number: 20030049610Abstract: The present invention relates to a method of detecting whether a target animal is Bovine Viral Diarrhea Virus (BVDV) positive or negative by determining whether a gp48 protein-specific reagent binds to a gp48 Bovine Viral Diarrhea Virus protein or protein fragment, which retains antigenic specificity, from a target animal's hair sample.Type: ApplicationFiled: August 9, 2002Publication date: March 13, 2003Inventors: Roy Huchzermeier, Edward Joseph Dubovi
-
Patent number: 6528057Abstract: This invention discloses a method for reducing the viral load by removal of viruses or fragments or components thereof from the blood by extracorporeally circulating blood through hollow fibers which have in the porous exterior surface, immobilized affinity molecules having specificity for viral components. Passage of the fluid through the hollow fibers causes the viral particles to bind to the affinity molecules thereby reducing the viral load in the effluent.Type: GrantFiled: August 30, 1999Date of Patent: March 4, 2003Inventors: Julian L. Ambrus, David O. Scamurra
-
Publication number: 20030039663Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 covalently bonded to CD4 or to succinyl concanavalin A. Also disclosed are immunological tests using the complex or antibody thereto for detection of HIV infection.Type: ApplicationFiled: July 17, 2001Publication date: February 27, 2003Inventors: Anthony L. Devico, Ranajit Pal, Mangalasseril G. Sarngadharan
-
Patent number: 6525179Abstract: A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-termninal Pro). Vaccinal and pharmaceutical compositions can contain one or more such peptides associated with carrier proteins, in multiple antigenic peptides or as part of recombinant proteins. Various combinations of the Epitope I through IV peptides can provide other compositions useful in eliciting anti-Tat antibodies which cross-react with multiple strains and variants of HIV-1 Tat protein.Type: GrantFiled: November 30, 1999Date of Patent: February 25, 2003Assignee: Thymon L.L.C.Inventor: Gideon Goldstein
-
Publication number: 20030022849Abstract: The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.Type: ApplicationFiled: April 4, 2001Publication date: January 30, 2003Inventor: Gwong-Jen J. Chang
-
Publication number: 20030013077Abstract: The present invention is directed to monoclonal antibodies capable of specifically binding to and recognizing an antigenic determinant (epitope) of the protein kaposin or a derivative therof, hybridoma cell lines producing said monoclonal antibodies, diagnostic systems for the detection of the presence of a kaposin protein or a derivative thereof as well as antibodies directed against the kaposin protein or a derivative thereof, methods for detection of the expression of kaposin protein or a derivative thereof in a biological sample, methods for the detection of antibodies directed against kaposin protein or a derivative thereof, uses of the monoclonal antibodies provided according to the invention and uses of the kaposin protein or a derivative thereof, each in diagnostics and therapy.Type: ApplicationFiled: May 16, 2001Publication date: January 16, 2003Inventors: Juergen Haas, Elisabeth Kremmer, Stefanie Kliche
-
Publication number: 20020155428Abstract: A novel immunodeficiency virus is disclosed which has the designation MVP-5180/91 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 920 52 318. The characteristics antigens which can be obtained from it and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the DNA and amino acid sequences of the virus.Type: ApplicationFiled: June 22, 2001Publication date: October 24, 2002Applicant: Dade Behring Marburg GmbH.Inventors: Lutz G. Guertler, Josef Eberle, Albrecht V. Brunn, Stefan Knapp, Hans-Peter Hauser
-
Patent number: 6458933Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.Type: GrantFiled: May 19, 1999Date of Patent: October 1, 2002Assignee: Immunomedics, Inc.Inventor: Hans J. Hansen
-
Publication number: 20020106639Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.Type: ApplicationFiled: August 20, 2001Publication date: August 8, 2002Applicant: University of SaskatchewanInventors: Li Wang, Lorne A. Babiuk, Andrew A. Potter, Philip Willson
-
Publication number: 20020090609Abstract: The present invention is directed to monoclonal antibodies capable of specifically binding to and recognizing an antigenic determinant (epitope) of the protein kaposin or a derivative thereof, hybridoma cell lines producing said monoclonal antibodies, diagnostic systems for the detection of the presence of a kaposin protein or a derivative thereof as well as antibodies directed against the kaposin protein or a derivative thereof, methods for detection of the expression of kaposin protein or a derivative thereof in a biological sample, methods for the detection of antibodies directed against kaposin protein or a derivative thereof, uses of the monoclonal antibodies provided according to the invention and uses of the kaposin protein or a derivative thereof, each in diagnostics and therapy.Type: ApplicationFiled: May 16, 2001Publication date: July 11, 2002Inventors: Juergen Haas, Elisabeth Kremmer, Stefanie Kliche
-
Publication number: 20020086034Abstract: Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.Type: ApplicationFiled: November 5, 2001Publication date: July 4, 2002Applicant: Probe International Inc.Inventor: Frank B. Gelder
-
Publication number: 20020086022Abstract: A composition and method for immune modulation of pathogenic infections is disclosed. More particularly, a composition and method for enhancing a mammal's ability to respond to, e.g., immunosuppressive pathogens, is disclosed in which a target antigen is mixed with a heterologous antisera specific or cross-reactive to that antigen to produce an inoculant. The inoculant is used to cause natural and specific immune responses to the heterologous antibodies to enhance complement fixation and specific humoral and cellular responses.Type: ApplicationFiled: February 9, 2001Publication date: July 4, 2002Inventor: Gary R. Davis
-
Patent number: 6413515Abstract: The present invention is drawn to avian vitellin antibodies that are immunologically reactive with HIV antigens, a process for the preparation thereof, a use thereof and a food substance in the form of a hen's egg containing the antibodies. The antibodies of the present invention are produced by immunizing hens with HIV antigens, in particular HIV core antigens and concentrating the antibodies in the egg yolk. The antibodies are suitable for passive immunization of mammals.Type: GrantFiled: July 13, 1998Date of Patent: July 2, 2002Assignee: Ovogenix Immunpharma GmbHInventors: Panagiotis Tsolkas, Hartmut Kobilke
-
Patent number: 6372216Abstract: A drug which protects individuals against hepatitis C virus (HCV) is made of HCV hyperimmune globulins, which guarantee a substantial hyperimmunity against HCV thanks to a substantial hyperconcentration of virus C neutralizing antibodies. This hyperconcentration is obtained from blood of a large number of anti-HCV positive blood donors. The material used for the preparation of the HCV hyperimmune globulins is made of up to 100% of anti-HCV positive blood units.Type: GrantFiled: August 26, 1998Date of Patent: April 16, 2002Inventor: Marcello Piazza